{"created":"2023-06-19T07:25:59.744547+00:00","id":14200,"links":{},"metadata":{"_buckets":{"deposit":"ed3cb9f4-4a59-4f68-b736-c35a3b888ff2"},"_deposit":{"created_by":91,"id":"14200","owners":[91],"pid":{"revision_id":0,"type":"depid","value":"14200"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00014200","sets":["212:253:333"]},"author_link":["32476","32479","32473","32471","32478","32484","32480","32472","32474","32481","32482","32477","32483","32475"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"205031211983601","bibliographicVolumeNumber":"7","bibliographic_titles":[{},{"bibliographic_title":"SAGE Open Medicine","bibliographic_titleLang":"en"}]}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System","subitem_title_language":"en"}]},"item_type_id":"3","owner":"91","path":["333"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-09-17"},"publish_date":"2020-09-17","publish_status":"0","recid":"14200","relation_version_is_last":true,"title":["Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System"],"weko_creator_id":"91","weko_shared_id":-1},"updated":"2023-06-19T07:45:14.585617+00:00"}